Human papillomavirus infection and cervical lesions in rheumatic diseases: A systematic review

Acta Reumatologica Portuguesa

Volumn 2016, Issue 3, 2016, Pages 184-190

  Raposo, Ana ^a   Tani, C ^b   Costa, J ^a   Mosca, M ^b  

^a Hospital Conde de Bertiandos   (Portugal)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Cervical lesions; Human papillomavirus; Review; Rheumatic diseases

Indexed keywords

COMPLICATION; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; RHEUMATIC DISEASE; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; RHEUMATIC DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 84994111937     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
2. Marrow J, Nelson L, Watts R, Isenberg D. Autoimmune Rheumatic Disease. Oxford University Press: Oxford. 1999.
3. Copper GS, Stroehla BC. The epidemiology of autoimmune di-seases. Autoimmun Ver. 2003;2:119-125.
4. Klumb EM, Araújo ML Jr, Jesus GR, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol. 2010 Jun;16(4):153-157
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
6. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities and cancer. Obs-tet Gynecol Clin North Am 2008;35:519-536.
7. Lee YH, Choe JY, Park SH, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci. 2010 Oct;25(10):1431-1437.
8. Santana IU, Gomes Ado N, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011 May;30(5):665-672.
9. Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev. 2014 Jul;13(7):730-735.
10. ACOG Practice Bulletin No. 131: Screening for Cervical Cancer. ACOG Committee on Practice Bulletins-Gynecology. Obstet Gynecol. 2012 Nov;120(5):1222-1238.
11. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case- control study. Ann Rheum Dis May 2013;72(5):659-664.
12. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-6255.
13. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255.
14. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
15. http://www.cochrane.org/handbook
16. http://www.prisma-statement.org
17. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2014 Mar 11.
18. Chang SH, Park JK, Lee YJ, et al. Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. Arthritis Res Ther. 2014 Aug 28;16(4):428.
19. Hemminki K, Liu X, Ji J, Försti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012 Oct;127(1):180-185.
20. Dugué PA, Rebolj M, Hallas J, Garred P, Lynge E. Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: populationbased cohort study. Int J Cancer. 2015 Mar 15;136(6):E711-719.
21. Esmaeili H, Ghahremanzadeh K. Association of Pap smear abnor malities with autoimmune disorders. Pak J Biol Sci. 2011 May 15;14(10):600-604.
22. Mercado U. Abnormal cervicovaginal cytology in women with rheumatoid arthritis. Ginecol Obstet Mex. 2010 Feb;78(2):94-98.
23. Gillet VG, Solomon DH, Shadick NA, et al. Behavioral and clini-cal factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis. J Womens Health (Larchmt). 2014 Sep;23(9):771-776.
24. Waisberg MG, Ribeiro AC, Candido WM, et al. Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study. Rheumatol Int. 2015 Mar;35(3):459-463.
25. Rojo Contreras W, Montoya Fuentes H, Gámez Nava JI, et al. Prevalence and cervical human papilloma virus associated factors in patients with rheumatoid arthritis. Ginecol Obstet Mex. 2008 Jan;76(1):9-17.
26. Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus. 2012 Apr21(4):365-372.
27. Cirpan T, Guliyeva A, Onder G, et al. Comparison of human papillomavirus testing and cervical cytology with colposcopic exa-mination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome. Eur J Gynaecol Oncol. 2007;28(4):302-306.
28. Tam LS, Chan PK, Ho SC, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken). 2011 Feb;63(2):269-276.
29. CostaPinto L, Olavarria VG, Grassi MF, et al. Prevalence of Chlamydia trachomatis endocervical infection in systemic lupus erythematosus patients and evaluation of the risk for HPV-induced lesions. Rheumatol Int. 2013 Mar.
30. Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013 Feb;33(2):335-340.
31. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010 Nov;19(13):1485-1491.
32. Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus. Clinics (Sao Paulo). 2013 Dec;68(12):1475-1480.
33. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011 Oct;63(10):3032-3027.
34. Dey D, Kenu E, Isenberg DA. Cancer complicating systemic lupus erythematosus a dichotomy emerging from a nested casecontrol study. Lupus. 2013 Aug;22(9):919-927.
35. Skare TL, da Rocha BV. Breast and cervical cancer in patients with systemic lupus erythematosus. Rev Bras Ginecol Obstet. 2014 Aug;36(8):367-371.
36. Martin M, Mougin C, Prétet JL, et al. Screening of human papillomavirus infection in women with systemic sclerosis. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-145-148.
37. Bernatsky S, Hudson M, Pope J, et al. Canadian Scleroderma Research Group. Reports of abnormal cervical cancer screening tests in systemic sclerosis. Rheumatology (Oxford). 2009 Feb;48(2):149-151.
38. Soybilgic A, Onel KB, Utset T, Alexander K,Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J Aug 7 2013;11(1):29.
39. Heijstek MW, Scherpenisse M, Groot N, Wulffraat NM, Van Der Klis FR. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol Sep 2013;40(9):1626-1627.
40. Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014 Aug;73(8):1500-1507.
41. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine Aug 19 2008;26(Suppl. 10):K1-K16.
42. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheuma-tic diseases. Ann Rheum Dis. 2011 Oct;70(10):1704-1712.
43. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-757 .
44. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-422.